RD
Roberto De Ponti
3B FUTURE Health Ventures
Monte-Carlo, Monaco
Overview
Roberto De Ponti is the Managing Director and General Partner at 3B Future Health Fund I & II, overseeing investments in companies like Fore Biotherapeutics and Geneos Therapeutics. With a background in pharmaceutical sciences and business development, he has held notable roles at Helsinn Group, Aadi Bioscience, and various biotechnology companies, contributing to advancements in drug development and technology transfer within the industry.
Work Experience
General Partner
2022 - Current
Board Observer
2023
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Raised $49,500,000.00 from Shanghai Healthcare Capital, 3B Future Health Fund, Global Bio Fund, Flerie Invest, Sante Ventures, Korea Investment Partners, Inovio Pharmaceuticals, Sante Ventures, Inovio Pharmaceuticals and Korea Investment Partners.
Board Member
2022
Board Observer
2022
Board Member
2021
Advisor
2020
Board Member
2016
Board Observer
2020 - 2024
Board Member
2018 - 2023
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
Raised $166,500,000.00 from Novartis Venture Fund, Wellington Management, SR One, OrbiMed, HBM Partners, 3B Future Health Fund, Medicxi, Samsung Securities and Cormorant Asset Management.
Board Member
2020 - 2022